Value
0.0/10data confidence 20%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
- ▸Expensive valuation
CTMX · Why this verdict
Why CytomX Therapeutics (CTMX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score3.7/10
ConfidenceHIGH
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The engine flagged CytomX's raw analyst target of $12.50 as implausible relative to the current price of $3.82, a 3.3x ratio, rejecting it and falling back to a technical take-profit instead. Bear case | A revised, plausible analyst target should emerge within 2 quarters as coverage updates, replacing the current technical-only fallback. | →Stable |
| CounterIf analyst coverage remains too thin or stale to produce a credible target, the stock could continue trading without a reliable fundamental upside anchor for an extended period. | ||
CytomX's 200-day moving average is still rising (+4.8%/30d) even though the price sits below it, which the engine classifies as a pullback within an uptrend rather than confirmed weakness. Momentum breakdown | Price reclaims the 200-day moving average within 2 quarters, confirming the uptrend read was correct. | →Stable |
| CounterAn RSI of 78 flags an overbought bear-rally condition, suggesting the recent bounce could fail rather than resume a genuine uptrend. | ||
CytomX carries below-average business quality (score 3.2, under the engine's 4.0 floor) and a rich-valuation flag despite an expensive-valuation read, driving the exit recommendation. Key risks | Quality score rises above 4.0 within 2 quarters if fundamentals meaningfully strengthen. | →Stable |
| CounterA Rule of 40 score of -198 and a weak 3/9 Piotroski F-Score both point to deep structural weakness that is unlikely to reverse quickly. | ||
CytomX is burning cash at -118% of revenue, a severe rate that raises questions about runway without additional financing or partnership deals. Quality breakdown | Cash burn rate improves to better than -80% of revenue within the next 2 reported quarters. | →Stable |
| CounterA biotech burning cash this fast, combined with a failing Rule of 40 score, faces meaningful dilution risk if it needs to raise capital, which could offset any operational improvement. | ||
A 16% short interest, flagged by the engine as justified given fundamentals, aligns with the upside-exhausted warning showing zero calculated upside at the current price. Key risks | Short interest declines below 10% of float or a new positive catalyst restores measurable upside within 2 quarters. | →Stable |
| CounterHigh, justified short interest combined with zero calculated upside suggests the market may already be efficiently pricing in the company's structural weaknesses, offering no near-term catalyst for reversal. | ||
The engine flagged CytomX's raw analyst target of $12.50 as implausible relative to the current price of $3.82, a 3.3x ratio, rejecting it and falling back to a technical take-profit instead.
→StableBear case
- Expectation
- A revised, plausible analyst target should emerge within 2 quarters as coverage updates, replacing the current technical-only fallback.
CounterIf analyst coverage remains too thin or stale to produce a credible target, the stock could continue trading without a reliable fundamental upside anchor for an extended period.
CytomX's 200-day moving average is still rising (+4.8%/30d) even though the price sits below it, which the engine classifies as a pullback within an uptrend rather than confirmed weakness.
→StableMomentum breakdown
- Expectation
- Price reclaims the 200-day moving average within 2 quarters, confirming the uptrend read was correct.
CounterAn RSI of 78 flags an overbought bear-rally condition, suggesting the recent bounce could fail rather than resume a genuine uptrend.
CytomX carries below-average business quality (score 3.2, under the engine's 4.0 floor) and a rich-valuation flag despite an expensive-valuation read, driving the exit recommendation.
→StableKey risks
- Expectation
- Quality score rises above 4.0 within 2 quarters if fundamentals meaningfully strengthen.
CounterA Rule of 40 score of -198 and a weak 3/9 Piotroski F-Score both point to deep structural weakness that is unlikely to reverse quickly.
CytomX is burning cash at -118% of revenue, a severe rate that raises questions about runway without additional financing or partnership deals.
→StableQuality breakdown
- Expectation
- Cash burn rate improves to better than -80% of revenue within the next 2 reported quarters.
CounterA biotech burning cash this fast, combined with a failing Rule of 40 score, faces meaningful dilution risk if it needs to raise capital, which could offset any operational improvement.
A 16% short interest, flagged by the engine as justified given fundamentals, aligns with the upside-exhausted warning showing zero calculated upside at the current price.
→StableKey risks
- Expectation
- Short interest declines below 10% of float or a new positive catalyst restores measurable upside within 2 quarters.
CounterHigh, justified short interest combined with zero calculated upside suggests the market may already be efficiently pricing in the company's structural weaknesses, offering no near-term catalyst for reversal.
TrendMatrix Research · core thesis
Engine thesis — one sentence
CytomX Therapeutics carries a rejected, implausible analyst target and a sub-floor quality score alongside severe cash burn, but its 200-day moving average is still rising and the setup reads as a pullback rather than a confirmed breakdown, keeping the position an exit candidate pending a reliable valuation anchor.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Rule of 40 | 3.0 |
| Piotroski F | 3.3 |
- ▸Cash-burning: FCF -118% of revenue
- ▸No competitive moat
- ▸Rule of 40: -198 (fail)
- ▸Weak Piotroski F-Score: 3/9
Growth
5.0/10data confidence 50%Momentum
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.5 |
| MACD | 8.9 |
| OBV | 10.0 |
| MA position | 7.2 |
| Volume | 0.3 |
- ▸Overbought bear rally (RSI 77)
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA but MA still rising (+4.8%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 4.6 |
- ▸Analyst upside: 228%
Insider
5.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.6 |
| notable moves | 7.0 |
- ▸Negligible insider selling — $4,953 (0.001% of mkt cap)
Peer rank
3.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 2.6 |
| quality rank | 2.6 |
| growth rank | 1.0 |
Technical
1.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.7 |
| support resistance | 0.8 |
| 52w position | 0.0 |
| gap | 6.0 |
Risk (lower is worse)
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.9 |
| days to cover | 1.1 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 3.1 |
| debt equity | 5.6 |
- ▸High short interest justified: 16%
- ▸High IV: 82%
- ▸Above max pain $1
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 0B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:5.8>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:32d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -54% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 6.5 could not lift the engine output above the verdict floor.
The strongest dimensions are Sentiment at 6.5, Insider at 5.9, and Momentum at 5.8; the weakest are Value at 0.0, Technical at 1.9, and Catalyst at 2.5. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Implausible Analyst Target Flag
Trip ifNo plausible analyst target is established within 2 quarterly refreshes, with the ratio to price staying above 2x, or the technical take-profit target is missed by more than 20%.
- P2Momentum Pullback Not Breakdown
Trip ifThe 200-day moving average slope falls below 0% over the next 30 days, or price fails to reclaim the 200-day moving average within 2 quarters.
- P3Quality Floor Exit Signal
Trip ifThe quality score stays below 2.5 at the next quarterly refresh, confirming the exit signal remains valid.
- P4Severe Cash Burn Risk
Trip ifCash burn rate falls below -150% of revenue, or the company announces a dilutive capital raise within the next 2 quarters.
- P5Short Interest Upside Exhausted
Trip ifShort interest rises above 25% of float while calculated upside remains at or below 0% for 2 consecutive quarterly refreshes.